Pharmacokinetics and Safety Profile of SNS812 , a First in Human Fully Modified siRNA Targeting Wide‐Spectrum SARS ‐ CoV ‐2, in Healthy Subjects
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70202 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Yi-Chung Chang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Oneness Biotech Company Limited, Taipei, Taiwan. Hauptthemen laut MEDLINE: SARS-CoV-2, RNA, Small Interfering, COVID-19 Drug Treatment. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Severe acute respiratory syndrome caused by the coronavirus (SARS‐CoV‐2) in the COVID‐19 pandemic has highlighted the need for effective treatments, as rapid viral mutations complicate therapeutic development. SNS812, a fully modified inhaled siRNA that targets the conserved RNA‐dependent RNA polymerase (RdRP) gene of SARS‐CoV‐2, has been shown to possess its suppression ability against wide‐spectrum SARS‐COV‐2 variants preclinically. To evaluate the safety and tolerability of inhaled SNS812 in healthy participants, a randomized, double‐blind, placebo‐controlled phase 1 trial was conducted. To justify the first‐in‐human inhalation study, this research was divided into two parts: single ascending doses (0.3, 0.6, and 1.2 mg/kg) and multiple doses (0.6 and 1.2 mg/kg) of daily inhalation for seven consecutive days to assess the safety, tolerability, immunogenicity, and pharmacokinetics of SNS812. Of the 44 participants, 3 in the 0.3 mg/kg single‐dose group, 2 in the 1.2 mg/kg multiple ascending doses group, and 1 in the placebo group reported treatment‐emergent adverse events (TEAEs). No serious adverse events (SAEs), treatment‐related adverse events (TRAEs), or TEAEs caused discontinuation or deaths were observed. PK showed rapid absorption of SNS812, with peak concentrations (median T max ) reached at 1.5–2 h, and an elimination half‐life (t 1/2 ) between 4.96 and 7.08 h. No antidrug antibodies (ADAs) were detected in either group. The results demonstrated that the first‐in‐human, fully modified with wide‐spectrum anti‐SARS‐COV2 siRNA by inhalation following a single dose and multiple doses was safe and well tolerated in healthy participants. Trial Registration: NCT05677893
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oneness Biotech Company Limited, Taipei, Taiwan.
- Microbio (Shanghai) Biotech Company, Shanghai, China.
- Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
- Genomics Research Center, Academia Sinica, Taipei, Taiwan.
- Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
ORCID-Profile: Ching-Wen Lin, Pan-Chyr Yang
Zitieren
APA
Chang, Y. C., Chen, Y. F., Yang, C. F., Ho, H. J., Yang, J. F., Chou, Y. L., Lin, C. W., & Yang, P. C. (2025). Pharmacokinetics and Safety Profile of SNS812 , a First in Human Fully Modified siRNA Targeting Wide‐Spectrum SARS ‐ CoV ‐2, in Healthy Subjects. Clinical and Translational Science. https://doi.org/10.1111/cts.70202
Vancouver
Chang YC, Chen YF, Yang CF, Ho HJ, Yang JF, Chou YL, et al. Pharmacokinetics and Safety Profile of SNS812 , a First in Human Fully Modified siRNA Targeting Wide‐Spectrum SARS ‐ CoV ‐2, in Healthy Subjects. Clinical and Translational Science. 2025. doi:10.1111/cts.70202
BibTeX
@article{Chang2025,
author = {Chang, Yi-Chung and Chen, Yi-Fen and Yang, Chi-Fan and Ho, Hui-Ju and Yang, Jen Fu and Chou, Yuan-Lin and Lin, Ching-Wen and Yang, Pan-Chyr},
title = {Pharmacokinetics and Safety Profile of SNS812 , a First in Human Fully Modified siRNA Targeting Wide‐Spectrum SARS ‐ CoV ‐2, in Healthy Subjects},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70202}
}
EUVIMED